Tenofovir maleate
Based on 10 publication(s) in Google Scholar
Tenofovir maleate (GS 1278 maleate; PMPA maleate) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
For research use only. We do not sell to patients.
- CAS No.: 1236287-04-9
- Formula: C13H18N5O8P
- Molecular Weight:403.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tenofovir maleate
More- Adv Sci (Weinh). 2022 Dec;9(34):e2203088. [Abstract]
- Nanoscale. 2017 Jul 13;9(27):9676-9684. [Abstract]
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]
- Sci Rep. 2017 Mar 15:7:44409. [Abstract]
- Antiviral Res. 2020 Jun:178:104786. [Abstract]
- Pharm Res. 2023 Nov;40(11):2597-2606. [Abstract]
- Drug Metab Dispos. 2026 Mar 2;54(5):100263. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Dec 15:1267:124803. [Abstract]
- bioRxiv. 2025 Aug 14:2025.08.14.670267. [Abstract]
- Charles University. 2019 Jun.
Customer Validation & Images
-
Bio/Physico-chemical Assay
Biological Activity
|
HIV-1 |
Tenofovir maleate displays cytotoxicity against HK-2 cells, with IC50 values of 9.21 μM at 48 h and 2.77 μM at 72 h determined by MTT assay. It reduces intracellular ATP levels, elevates oxidative stress and protein carbonylation, and triggers mitochondria-mediated apoptosis in HK-2 cells[1].
Tenofovir maleate formulated with M48U1 in 0.25% HEC inhibits the replication of R5-tropic HIV-1BaL and X4-tropic HIV-1IIIb in activated PBMCs, and suppresses a panel of laboratory HIV-1 strains and patient-derived primary HIV-1 isolates. The combined formulation of Tenofovir maleate and M48U1 in 0.25% HEC delivers synergistic antiretroviral activity against R5-tropic HIV-1BaL infection and exhibits no cytotoxicity toward PBMCs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1236287-04-9
-
Molecular Weight 403.28
-
Formula C13H18N5O8P
-
SMILES
C[C@@H](OCP(O)(O)=O)CN1C=NC2=C(N)N=CN=C12.O=C(O)/C=C\C(O)=O
-
Synonyms
GS 1278 maleate; PMPA maleate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]2022 Dec;9(34):e2203088. PMID: 36257906 -
Nanoscale
2017 Jul 13;9(27):9676-9684. PMID: 28675222 -
Int J Antimicrob Agents
2019 Dec;54(6):814-819. PMID: 31479744 -
Sci Rep
2017 Mar 15:7:44409. PMID: 28294122 -
Antiviral Res
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]2020 Jun:178:104786. PMID: 32251767 -
Pharm Res
Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney Disease. [Abstract]2023 Nov;40(11):2597-2606. PMID: 37704895
Tenofovir maleate purchased from MedChemExpress. Usage Cited in: Pharm Res. 2023 Nov;40(11):2597-2606. [Abstract]
Uremic solute inhibition of Tenofovir uptake. Human OAT1 and OAT3-overexpressing and mock-transfected HEK-293 cells were used for inhibition studies. Radiolabeled Tenofovir (0.1 μM) was added with potential inhibitors at specified concentrations for 5 min at 37 °C. Results of Tenofovir uptake were normalized to % of vehicle controls. IC50 shown in insets were calculated based on nonlinear regression curves.
-
Drug Metab Dispos
A minimal physiologically based pharmacokinetic model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis. [Abstract]2026 Mar 2;54(5):100263. PMID: 42085925 -
J Chromatogr B Analyt Technol Biomed Life Sci
Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma. [Abstract]2025 Dec 15:1267:124803. PMID: 41072339 -
bioRxiv
Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580. [Abstract]2025 Aug 14:2025.08.14.670267. PMID: 40832229 -
Protocol
Cells are plated into 48-well tissue culture plates (39,000 cells/mL) and allowed to grow for 48 h followed by treatment with vehicle or Tenofovir. Following the treatment period, cell viability is assessed using the MTT assay. The MTT assay relies on the conversion of tetrazolium dye 3-(4,5-dimethlthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan by NAD(P)H-dependent oxidoreductases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Twenty adult chronic WHV carrier woodchucks are stratified equally by age, sex, body weight, and serum GGT activity into five treatment groups consisting of four animals each: (i) Tenofovir Disoproxil Fumarate at 15.0 mg/kg once per day, (ii) Tenofovir Disoproxil Fumarate at 5.0 mg/kg/day, (iii) Tenofovir Disoproxil Fumarate at 1.5 mg/kg/day, (iv) Tenofovir Disoproxil Fumarate at 0.5 mg/kg/day, and (v) a placebo control. The woodchucks are treated daily for 4 weeks and observed for an additional 12 weeks following cessation of drug treatment[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
References
[1]. Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18(3). [Content Brief]
[2]. Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018. [Content Brief]
[3]. Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098. [Content Brief]
[4]. Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tenofovir maleate Related Classifications
HY-13910B Related Classifications
Powered by Bioz